Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Hormone Replacement Therapy
Desert Mobile Medical | Concierge Physicians is Now Offering Virtual Appointments to Help Avoid the Spread of COVID-19 – MENAFN.COM
Posted: May 9, 2020 at 9:54 am
(MENAFN - GetNews)
Scottsdale, AZ - Getting medical help and attention does not have to be a stressful process. Essentially, a patient does not have to wait long hours to see a doctor for minor or major complaints and this is why the team at Desert Mobile Medical | Concierge Physicians has repackaged their medical services to offer patients the concierge and mobile medical attention that they deserve. At Desert Mobile Medical | Concierge Physicians, the doctors and primary healthcare providers come to patients wherever they may be, whether at home or work, to deliver the best quality of medical care services, all at an affordable price.
With the current global pandemic brought on by the novel coronavirus, Desert Mobile Medical | Concierge Physicians is working hard to ensure that the healthcare needs of its patients are met. This major concern has led to the announcement of offering the option for virtual appointments. With the capability to do virtual appointments, patients will be offered concierge services that are in line with the recommended social distancing and self-quarantine guidelines while still being able to dispense appropriate medications as necessary.
With Desert Mobile Medical | Concierge Physicians, patients can worry less about exposing themselves to more danger and health risks while waiting at the hospital or doctor's office for their appointments. The team of mobile medical doctors are always ready and on standby to attend to patients virtually or by visiting them in the comfort of their own home.
The concierge physicians at Desert Mobile Medical | Concierge Physicians are unique in the fact that they cut out the middle man (health insurance) so that they can spend more time with YOU, the patient. They have structured their model to be able to provide the highest quality of care while still saving their patients money, whether they have insurance or not. Over 70% of their patients have health insurance and have still found that Desert Mobile Medical provides better care at a lower cost.
Did you know that 90% of health issues can be solved with Direct Primary Care? Desert Mobile Medical | Concierge Physicians is Healthcare Built Around You' meaning they are convenient (since they go to your home), they are flexible (they typically accommodate for same day or next day appointments), and affordable (they take out the middleman, health insurance, to give you quality healthcare with no hidden costs or impossibly complicated invoices).
Overall one of the biggest benefits is saving on lost time. Not only the lost time of driving to the doctor's office and then waiting there for hours, but also because they give you the time needed so they can make sure you have the best care resulting in a more effective you.
Describing the personalized and unhurried care of a concierge doctor offered by the medical physicians at Desert Mobile Medical, a patient left a 5-star review for the online doctor saying, 'This is a fantastic service and I'm glad I found Dr Goel. He takes his time listening to your issue and explains what and why he is treating you the way he is. He doesn't have the typical just do as I say and all will be better' attitude. His focus on preventative care is unique, he prefers to prevent health problems from occurring rather than treat them after they happen. Being able to call, video chat or just message when you need him is the future of doctor appointments. He is quick to respond and does what he can to address your needs as quickly as he can.
Desert Mobile Medical | Concierge Physicians is currently accepting new patients, as they provide a full suite of the most important mobile doctor services to support your vibrant good health, even during this challenging time, by offering the option to visit your home or perform a virtual appointment.
The concierge physician will ensure that patients, during the pandemic, are well catered to. If a patient chooses to have a mobile doctor visit their home for their appointment, prior to their visit, the doctor will maintain COVID-19 safety procedures that will ensure the continued protection of patients from the global pandemic.
Desert Mobile Medical | Concierge Physicians offers services such as: hormone replacement therapy, mobile lab tests, vaccinations, in-home medical dispensing, mobile diagnostic imaging services, direct primary care services, as well as physical and massage therapy services.
Desert Mobile Medical | Concierge Physicians is headquartered at 9300 E Raintree Dr Suite 130 Suite 2, Scottsdale, AZ 85260. Contact their team via phone at (480) 427-0002 or send online inquiries via email to . For additional information regarding their services, visit their website.
Media Contact Company Name: Desert Mobile Medical Contact Person: Dr. Paresh Goel Email: Send Email Phone: (480) 427-0002 Address: 9300 E Raintree Dr Suite 130 Suite 2 City: Scottsdale State: AZ Country: United States Website: http://desertmobilemedical.com/
MENAFN0805202000703268ID1100137432
See original here:
Desert Mobile Medical | Concierge Physicians is Now Offering Virtual Appointments to Help Avoid the Spread of COVID-19 - MENAFN.COM
Posted in Hormone Replacement Therapy
Comments Off on Desert Mobile Medical | Concierge Physicians is Now Offering Virtual Appointments to Help Avoid the Spread of COVID-19 – MENAFN.COM
The secret life of an anonymous speechwriter to the stars – The Guardian
Posted: May 9, 2020 at 9:54 am
I write speeches for people who can barely read their scripts because public speaking makes them nervous (statistically, public speaking is the number one fear, worse even than death). I write for people who are so compelling and beautiful that they could recite the alphabet and get a standing ovation. I write arguments that are recited in the House and Senate, in the seats of power. My words are on television and in stadiums that hold thousands of eager listeners. Im not there at all. The speeches, toasts and rallying cries I write go further than I ever will: I may not be seen, but I am heard. The words that do not matter when I speak for myself are amplified when I put them in the mouths of others. Because as anyone knows, its not just the words that matter. Its who says them, and when, and how.
Before I started writing for reality TV stars, musicians, political leaders and lecturers, I assumed that everyone wrote their own lines. Why wouldnt I think that? A well-written speech sounds like the person whos giving it. Or at least, it sounds like the person the speaker wants you to believe they are. Now I know that I was naive to assume that any public figure, even one who is a good writer, writes their own speeches and biographies and other ephemera. Ive learned that you are probably hearing something written in the style of by a very talented mimic.
Im an excellent mimic. This makes me a good speechwriter, but when I came out as nonbinary trans, it also became a survival skill. My welfare often depends on whether the non-transgender people around me see me as fully human and that means knowing exactly what to say, when, and in what tone. I needed to sound confident but not overbearing; friendly but not obsequious. My masculine presentation had to be balanced by kindness, consideration of others, and a willingness to cede the floor. I couldnt afford to blunder through any conversation, and I approached every interaction with more awareness and intention than ever before. Honestly, I spent a lot of time thinking about what Fred Rogers would say.
The only place where I didnt need to moderate my tone, where I could speak freely, was in my addiction recovery community. Through the first, dramatic stages of my transition, when my voice broke and when I was so afraid that my anger and panic was unwelcome in the world, the friends I knew there listened to me and encouraged me to keep sharing. They understood that, for people like us, honesty is lifesaving. People who swallowed their feelings relapsed, disappeared and died. I lost many friends to overdoses and substance-related accidents and suicides, silent deaths that went unacknowledged outside of our community. I kept showing up, and I kept talking. Tears, bile, all of me was welcome.
Outside of meetings, I couldnt express myself with the same openness. Although the words I spoke didnt change, my voice and the way I sounded altered the way that others heard me. Short statements, in a deep, gruff voice, can be heard as controlling, dismissive or rude, a sign of un-self-aware male privilege. The anger that commanded respect and interest when I presented as female became a liability as my voice lowered, acquiring the tones of patriarchy. Each word carried more weight, bigger consequences than before. Id had practice writing speeches for other people. Now, I had to learn new lines that were right for my voice and the body that carried it. Once my voice hit a certain frequency, I became my own ghostwriting client: how did I want to be perceived? What character was I playing now?
I started ghostwriting at the end of Barack Obamas first term as president. His writer, Jon Favreau, wrote sonorous lines for Obama. Those wide, soft vowels became musical. Like Winston Churchills, Obamas speeches were written in psalm-form, blocks that mimic the way people speak when they are going off script. The euphony in Obamas campaign speeches, alternately fiery and soothing, changed to the melody of authority once he was in office. I listened to Obama lean on the linguistic patterns of pastors, visionaries and teachers. His speeches used simple, two-syllable words, to avoid making him seem too much like an arugula-eating liberal. They had a signature three-verse structure, with a bridge in the middle. Once Id heard this music, I couldnt un-hear it.
The first time I wrote a speech for money, I was working as a research assistant for the manager of a hedge fund in Oregon. Dave* was also a member of a secret society that met annually for a black-and-white gala dedicated to the brilliance of Winston Churchill. At this gala, he told me, everyone wore a real tuxedo, penguin-style, with tails and a top hat. They slugged gallons of Churchills favorite drink Beefeater martinis and chomped cigars. The gala was a tense time, Dave explained, because of the elaborate system of speeches. Depending on his place in the hierarchy, any one of the guests would be expected to rise and disgorge a brief, bon-motstudded toast.
At that time, my voice was much higher, smoother and sweeter. I had not started hormone replacement therapy (HRT), and I still sounded like a woman. People dont listen to womens voices; they hear women speaking, but not the words they say. Research shows that voices with higher pitches, vocal fry, feminine vocal characteristics like a lisp, and gendered vocal tics such as the repeated use of like are ignored. Over five decades, the fundamental frequency of a test group of womens voices dropped by 23Hz, which correlates with womens entry into a previously male-dominated workplace. I did not have a high voice, but it was undeniably female. I was used to being read as a woman, discounted and ignored. The idea of Dave saying my words to a group of powerful, wealthy strangers shook something loose in me.
There were two caveats: the toast had to include a quote from Churchill that had never been used before, in the hundred-year history of the club; and it had to be short. I labored over this speech, getting stuck on all of the things I would say if I were the one in the spotlight. I could only hear myself and my own opinions. A speech like that would never make it into Daves shirt pocket, much less be read at this gala. I needed to alter my voice. I spent eight hours a day listening to Dave on the phone, as he bragged about the pitchers of sangria the waitress used to bring them from the VQ Cafe, back when Dave was a big deal, when he was young, before this dotcom bullshit. I knew exactly what he sounded like and how he wanted to be heard.
I imagined him, drunk and puffy in his Churchill costume, one hand on the tablecloth next to a plus-size martini and a half-eaten slab of roast beef smeared across a china plate, listing to port as he read the remarks Id written for him. I heard his voice, the money-basted sound of arrogant privilege. I looked at the toast again, picked up my pen, and started over. I was a good listener. I nailed it.
The speech I wrote for Dave was the first of many, and it worked because I stopped trying to write a speech and started imitating the best version of Dave. I wrote a script for the character he wanted to play that night, and it worked. For the duration of my job with him, I wrote his emails, fundraising letters and other speeches. I mocked him to my friends, pitch-perfect lines that could have come right out of his mouth. I said the things he hadnt thought of yet.
For the next six years, I wrote more speeches, lectures and manuscripts, mostly for people who didnt know who I was, aside from the writer. I didnt identify my gender when I did this work. I was just a voice on the phone, transcribing our conversations into ideas and paragraphs that would move an audience to the desired result. Want a million dollars in donations? I can write a speech that will achieve that. Want to pass lifesaving legislation? I can write one for that too. Want to change the way your audience feels about love, survival, health, politics, literature, community or hope? Thats my bread and butter. Sometimes, I wrote for people whose beliefs were diametrically opposed to my own. They were not difficult to mimic. In fact, those pieces were the easiest, because I could never confuse their voices for my own.
Then I started my physical transition. Within a couple of months on testosterone, I developed the usual hoarseness as the hormones affected my vocal fold structure, tissue integrity and thickness. My voice started to drop, a second adolescence. Yet my expressions did not change. When I spoke, my cadence and word choices were still female. I wandered around my subjects and avoided direct answers or simple statements. I preferred to agree without saying yes, refuse without saying no. I wrote in my clients voices, transcribing their desires. I went to meetings and barked about the unmanageable problems in my life: cravings, friends who caught a bad batch and didnt wake up, my disintegrating relationship with my immediate family, my fear of the painkillers that came with top surgery. It was a hard time. I was grateful for any ear, any place where I could go off script.
As I became audibly and physically queer, those spaces disappeared entirely. Id been socialized as female and already knew not to be abrasive in mixed company or share my opinions; before my transition, Id had the distinct experiences of being ignored and talked over by men. However, after a while, cis women stopped hearing me too. Or they heard me but didnt listen. My voice was husky from the early months of HRT. It was weak and airy, as though I had a throat cold; it vaporized in group conversations. I coughed out an idea and watched it disappear. More than once, I shared an opinion in a group and was ignored, but I noticed that when someone else parroted what Id said, they were acknowledged. I was afraid to speak up and challenge others conditional acceptance of me. I had so few places to go where I felt safe, giving up some airtime felt like a fair trade.
I stopped making declarative statements, stopped asserting myself. I kept quiet and listened. I reasoned that my actions spoke louder than my words, and that I didnt need my opinions or feelings acknowledged in order for them to be valid. There was no point in debating with people who didnt hear me when I spoke. I could let most ideas float by, unchallenged and unexplored. They were just noise. They didnt matter.
Then, I was hired to write a piece of testimony for a client, woven together with his personal experience with recovery from addiction. I wrote the first draft straight, drawing from his notes, but I barely had to glance at them to know what I needed to say. I was listening to my own story. Like me, my client had lost friends to preventable overdoses. He, too, struggled to make his voice heard outside of the recovery community. Unlike me, he had found a way and was using his story to create real change. He had access to lawmakers: he was meeting with Congress members, pushing policy to make sure naloxone was available in every sober living home in his state. His story was powerful and it burned in my ears as I wrote it down. I believed what I was writing; I felt the message. Although I wrote in my clients distinctive voice, I knew I was also speaking for myself.
I read the speech out loud in my studio to a hanging photo of my father. I recited it in the park to a smattering of pigeons. I heard the speechs music and the deep, implacable rage underneath it. Although Id written it for my client, I heard my own voice in it. What would I say if I wasnt afraid? I wished I could stand on a stage in front of hundreds of sign-clutching protesters and demand justice, as this client would, jabbing his finger toward the sky. Our time is now. What would I say if people actually listened? I went over the speech again, fine-tuning its message. I imagined my client, one of the bravest people I knew. I wanted to give him words that would speak for him, for me, for everyone who was listening. Every syllable had to move his audience. Lives hung in the balance: if the speech failed, that was one step back. The legislation tied to it might not pass. More people would die.
When I was done, I felt like Id handed over a piece of my heart. Id never cared so much before or put all of myself on the page that way. Id given the best of myself, the self I wished others perceived.
My client delivered the speech. His legislation passed. The news wire picked up the story, amplifying his words. The ripples spread. Later that week, I watched a video of my client on the day he read his story and had the jarring experience of hearing my voice come out of someone elses mouth. From his inflections to his gestures, we could have been mirror images. The crowd roared in all the right places. They resonated with the same passion Id felt when my client first hired me to write for him: his courage, transmittable, went from him to me to the massive audience that hung on his every word.
Although Id set out to be the channel for my clients voice, I had received so much more. I felt his confidence as he spoke. Writing for him awakened my own voice. The next time I heard an acquaintance sneer about dirty addicts who were a waste of resources, I cleared my throat. The person turned to me, eyes narrowed.
Fewer than 10% of people with substance use disorder ever get help of any kind because of stigmatizing language like dirty or clean, I said. The speech Id written trickled out of my mouth. Even people with substantial periods of recovery need support for their mental health. Addiction isnt a moral failing, and its not fair to frame it that way.
To my surprise, they nodded, leaned closer. They heard me. They listened.
* Daves name has been changed.
This story originally appeared on the digital storytelling platform Narratively. Looking for more great work? Here are some suggestions:
Read more:
The secret life of an anonymous speechwriter to the stars - The Guardian
Posted in Hormone Replacement Therapy
Comments Off on The secret life of an anonymous speechwriter to the stars – The Guardian
Filsuvez Confirmed as Global Brand Name for Ap101 – GlobeNewswire
Posted: May 9, 2020 at 9:54 am
AMRYT PHARMA PLC
(Amryt or the Company)
FILSUVEZ CONFIRMED AS GLOBAL BRAND NAME FOR AP101
Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that the global brand name for its lead development product AP101 will be FILSUVEZ.
Amryt announced on 23 April 2020 that the Company has completed recruitment into its Global Phase 3 clinical study (EASE) in Epidermolysis Bullosa (EB) and anticipates top line data read out in late Q3 / early Q4 2020.
Establishing the brand name for AP101 is another important step forward in ensuring readiness for the global launch of FILSUVEZ.
About EB EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration (FDA). The European and US market opportunity for EB is estimated by the Company to be in excess of $1 billion.
About FILSUVEZFILSUVEZ is a potential treatment for EB, a rare, chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate, affecting infants, children and adults, for which there is currently no approved treatment.It is estimated that the incidence of EB is approximately 1 in 20,000, which implies that there are as many as 30,000 affected individuals in the US and over 500,000 worldwide.
In March 2017, Amryt commenced EASE, a Phase 3 prospective double-blind randomised placebo controlled efficacy and safety study of FILSUVEZ in patients with dystrophic and junctional EB. EASE is the largest ever global Phase 3 study conducted in patients with EB, operating across 55 sites in 27 countries globally. In January 2019, Amryt reported the outcome of an unblinded interim efficacy analysis, at which point an Independent Data Monitoring Committee recommended continuing the trial.
In July 2018, FILSUVEZ was granted Rare Pediatric Disease Designation by the FDA. This means that if a New Drug Application (NDA) for FILSUVEZ is approved, the Company expects to be eligible to receive a Rare Pediatric Disease Priority Review Voucher that can be used, sold or transferred.
FILSUVEZ was granted Fast Track Designation by the FDA in September 2019. The Fast Track programme is designed to accelerate the development and review of products such as FILSUVEZ, which are intended to treat serious diseases and for which there is an unmet medical need. Fast Track Designation enables more frequent communication with the FDA. Amryt has received FDA agreement that FILSUVEZ can be submitted for a rolling review NDA which is planned in the coming months and will request a priority review in the US. Amryt also intends to pursue an accelerated assessment in the EU.
FILSUVEZ has been granted Orphan Drug status for the treatment of EB in the EU and the US. Should FILSUVEZ be granted approval, it should be entitled to Orphan Drug exclusivity for the treatment of EB, extending seven years in the US and ten years in the EU from the date of approval in the respective jurisdictions.
Dr Joe Wiley, CEO of Amryt Pharma, commented:Establishing FILSUVEZ as the global brand name for AP101 is another important step in our launch readiness planning for FILSUVEZ. This alongside our recent completion of recruitment into the EASE study represents further progress as we endeavour to develop a therapy for patients with EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.
Enquiries:
Rory Nealon, CFO/COO
Shore Capital
Stifel
+353 (1) 679 6363
Consilium Strategic Communications
LifeSci Advisors, LLC
About Amryt
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Amryts commercial business comprises two orphan disease products.
Juxtapid/ Lojuxta (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the trade name Juxtapid) and in the EU (under the trade name Lojuxta). HoFH is a rare genetic disorder which impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature cardiovascular disease.
Myalept / Myalepta (metreleptin) is approved in the US (under the trade name Myalept) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta) for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. Metreleptin is also approved for lipodystrophy in Japan. Generalised and partial lipodystrophy are rare disorders characterised by loss or lack of adipose tissue resulting in the deficiency of the hormone leptin, produced by fat cells and are associated with severe metabolic abnormalities including severe insulin resistance, diabetes, hypertriglyceridemia and fatty liver disease.
Amryt's lead development candidate, FILSUVEZ is a potential treatment for the cutaneous manifestations of Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the FDA. The European and US market opportunity for EB is estimated by the Company to be in excess of $1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, including products, please visitwww.amrytpharma.com.
Forward-Looking StatementsStatements in this announcement with respect to Amryt's business, strategies, timing for completion of and announcing results from the EASE study, the potential impact of closing enrollment in the EASE study, as well as other statements that are not historical facts are forward-looking statements involving risks and uncertainties which could cause the actual results to differ materially from such statements. Statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the companys current beliefs and assumptions and are based on information currently available to management.
See the article here:
Filsuvez Confirmed as Global Brand Name for Ap101 - GlobeNewswire
Posted in Hormone Replacement Therapy
Comments Off on Filsuvez Confirmed as Global Brand Name for Ap101 – GlobeNewswire
Bringing the immune system into balance may be the key to managing debilitating thyroiditis – St George News
Posted: April 27, 2020 at 2:52 pm
Stock image, St. George News
FEATURE When it comes to hypothyroid patients in the United States, approximately 80-90% of them have an autoimmune disease called Hashimotos thyroiditis.
With Hashimotos, an errant immune system attacks and chews up the thyroid gland to the point where it becomes inflamed, swollen, impaired and unable to produce the hormones it should to maintain health and quality of life. Sometimes during the typically long process of destruction that characterizes Hashimotos, the gland even dumps too much hormone for short periods of time, creating hyper/hypo cycles that can drive patients and their doctors to the end of their ropes.
Despite Hashimotos dominance in the thyroiditis category, doctors seldom diagnose it via lab tests because insurance companies are unwilling to pay for the tests. They know that conventional medical treatment for Hashimotos hormone replacement therapy is the same as the treatment for other forms of hypothyroidism.
The thinking goes like this: If the treatment is going to be the same no matter what, why pay for extra testing? Seems logical enough. But is it? Lets explore.
A large number of my patients are middle-aged women who come to my office after having been told by doctors that they are hypothyroid. They have been taking various hormone replacement medications to get their laboratory numbers especially their pituitary TSH and thyroid T4 levels back into normal ranges.
Despite the treatment, including jumps in dosage, these women continue to exhibit many different symptoms, including symptoms of hypothyroidism that hormone replacement was supposed to alleviate.
When that approach failed to relieve symptoms for these women, another diagnosis often followed, usually from the following sickness menu: depression, cyclothymia, PMS, chronic fatigue syndrome, fibromyalgia and anxiety disorder. For these women, the additional diagnoses have meant more drugs and more side effects from those drugs yet little, if any, relief from the misery they suffer. What is going on?
The immune system has two sides. One side attacks invaders while the other side creates antibodies that tag invaders for later attack and removal. With Hashimotos, one side has gone hyper, tricking the body into attacking its own cells. Further, when a confused immune system creates errant antibodies that attack the thyroid, those inflammatory antibodies also convince other body cells to resist thyroid hormones present in the bloodstream.
Thats not good.
Thyroid hormones are meant to trigger important metabolic functions within cells. When the cells resist, the hormones already present dont work well and energy levels tank. That is why a patient can have adequate levels of thyroid hormones in the bloodstream and still have symptoms of low thyroid.
The key to managing the immune system of a Hashimotos patient is to find out whether the patient indeed has Hashimotos. We then can find out what side of the immune system is out of kilter and bring it back into balance with the other. This doesnt mean suppression, which is dangerous; it means modulation.
Once the proper laboratory panels are run including a comprehensive thyroid panel and after looking for blood sugar disorders, other hormone imbalances, anemia patterns and adrenal gland dysfunction, the needed approach usually becomes quite clear.
But that approach must be tailored to each individual. One size does not fit all because too many things are often out of kilter at the same time with Hashimotos. Whats more, doctors need time to truly listen to patients, a service that is in short supply under todays insurance-driven health care system.
Treating Hashimotos, whether actively diagnosed or not, as a thyroid disease requiring only hormone replacement is fighting the wrong battle. Hashimotos thyroid is basically an immune system problem that just happens to be targeting the thyroid. Manage the immune system problem well and the thyroid gland will often recover stability.
Moreover, further damage and continued symptoms can usually be averted by finding out what triggered Hashimotos in the first place, managing the diet, evaluating GI function for issues, altering general lifestyle behavior and supplementing with immune-system modulating plant extracts commonly used in functional medicine.
Yes, hormone replacement may still be needed if too much damage has been done and the gland is no longer able to produce sufficient amounts. Although Hashimotos is the result of some form of genetic susceptibility to environmental and other triggers and cant be reversed in the current science, it can be managed and held at bay very well to regain quality of life.
Written byEast West Health Wellness Experts.
This article was first published in St. George Health and Wellness magazine.
Email: news@stgnews.com
Twitter: @STGnews
St. George Health and Wellness magazine joins with St. George News to provide feature articles focused on fitness, nutrition, health, mind and body, and family wellness. The St. George Health and Wellness magazine is distributed to hundreds of locations every other month throughout St. George and surrounding areas. Articles are written by local experts and providers - for more information on any of these, visit http://www.saintgeorgewellness.com.
See more here:
Bringing the immune system into balance may be the key to managing debilitating thyroiditis - St George News
Posted in Hormone Replacement Therapy
Comments Off on Bringing the immune system into balance may be the key to managing debilitating thyroiditis – St George News
Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors – Cancer Network
Posted: April 27, 2020 at 2:52 pm
In a research letter published inJAMA Network Open, researchers suggested that there is a correlation between improved survival and adjuvant chemoendocrine therapy, specifically for hormone receptor (HR)-positive, ERBB2 (formerly HER2/neu)-positive tumors 8 mm to 10 mm.
According to the researchers, recurrence rates for patients with HR-positive, ERBB2-positive tumors range from less than 5% up to 25% at 5 years, with or without adjuvant treatments. With randomized trial data on the role of chemotherapy for small tumors currently lacking in this disease space, the cutoff size at which chemotherapy should be omitted remains uncertain.
While relevant prospective clinical trials continue to accrue data, the researchers indicated that this data could help clinicians in decision-making regarding adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast cancers.
It is evident that tumors 10 mm and smaller represent a heterogeneous group whose treatment should be tailored to improve the risk-to-benefit ratio of systemic therapy, the authors wrote. We acknowledge the inherent challenges of diagnostic concordance in the context of millimeter-based decisions, which underscores the importance of expert pathology review.
Using the US National Cancer Database, researchers queried for female patients with HR-positive, ERBB2-positive pT1a-bN0 breast cancer diagnosed between 2010 and 2015 who received hormone therapy with or without chemotherapy. The Kaplan-Meier method and Cox multivariable analysis were then performed to evaluate overall survival, and propensity score matching was based on the nearest neighbor method in a 1:1 ratio without a replacement.
Overall, 10,065 patients were identified for the study, including 5,346 patients who received chemotherapy and 4,719 patients who did not. On multivariable analysis, multiagent chemotherapy was correlated with an improved overall survival (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90;P= 0.006), and tumor size as a continuous variable was associated with worse mortality (for every 1-mm increase, HR, 1.07; 95% CI, 1.03-1.12;P= 0.002). Moreover, there was a statistically significant interaction found between multiagent chemotherapy and tumor size (Pfor interaction = 0.02).
Cox multivariable analysis was repeated with each tumor size cutoff, ranging from 2 mm to 9 mm, and an 8-mm cutoff was suggested to be statistically significant (Pfor interaction = 0.01), with a large effect size and narrow 95% CI on subgroup analysis. Further, multiagent chemotherapy was not associated with improved overall survival for tumors smaller than 8 mm (HR, 1.00; 95% CI, 0.70-1.43;P= 0.99), compared with tumors 8 mm to 10 mm, which therefore favors the use of chemotherapy (HR, 0.53; 95% CI, 0.36-0.78;P= 0.001). Additionally, comparable findings were seen in 1,641 and 648 matched pairs, respectively (tumors <8 mm, HR, 0.88; 95% CI, 0.58-1.34;P= 0.55; tumors 8-10 mm, HR, 0.48; 95% CI, 0.27-0.85;P= 0.01).
Our study is limited by the lack of specific systemic therapy regimens, the authors wrote. Subgroup analysis using this cohort would be difficult because of the small sample sizes, as neither systemic therapy alone is a definitive recommendation by [the] National Comprehensive Cancer Network in this setting.
Because the National Cancer Database is a deidentified data set, ethical approval was waived by the Roswell Park Comprehensive Cancer Center institutional review board. Moreover, the study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Reference:
Ma SJ, Oladeru OT, Singh AK. Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor-Positive, ERBB2-Positive, Node-Negative Breast Cancer.JAMA Network Open. doi:10.1001/jamanetworkopen.2020.2507.
Read the original here:
Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors - Cancer Network
Posted in Hormone Replacement Therapy
Comments Off on Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors – Cancer Network
Hormone Replacement Therapy (HRT) Market 2020 COVID19 Impact Analysis on Key Players | Spice Technologies, FreshBooks, ActCAD and Others – Latest…
Posted: April 27, 2020 at 2:52 pm
Futuristic Reports, The growth and development of Global Hormone Replacement Therapy (HRT) Market Report 2020 by Players, Regions, Type and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Hormone Replacement Therapy (HRT) Market analysis deliver important insights and provide a competitive and useful advantage to the pursuers. Hormone Replacement Therapy (HRT) processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools. Simultaneously, we classify different Hormone Replacement Therapy (HRT) market based on their definitions. Downstream consumers, and upstream materials scrutiny are also carried out. Each segment includes in-depth explanation of the factors that are useful to drive and restrain it.
Key Players mentioned in the study are Spice Technologies, FreshBooks, ActCAD, Bluebeam Software, Trimble, Graphisoft, Clearview Software, progeSOFT, Chief Architect, Vectorworks, Asynth, Computer Systems Odessa, Base Builders, Newforma, Tekla, eTeks, SoftPlan Systems, Floorplanner, RoomSketcher, Gather
For Better Understanding, Download FREE Sample Copy of Hormone Replacement Therapy (HRT) Market Report @ https://www.futuristicreports.com/request-sample/66100
Key Issues Addressed by Hormone Replacement Therapy (HRT) Market: It is very significant to have Hormone Replacement Therapy (HRT) segmentation analysis to figure out the essential factors of growth and development of the market in particular sector. The Hormone Replacement Therapy (HRT) report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for player to focus and highlight on.
Businesses Segmentation of Hormone Replacement Therapy (HRT) Market:
On the basis on the applications, this report focuses on the status and Hormone Replacement Therapy (HRT) outlook for major applications/end users, sales volume, and growth rate for each application, including-
Small and medium-sized enterprises Large enterprises
On the basis of types/products, this Hormone Replacement Therapy (HRT) report displays the revenue (Million USD), product price, market share and growth rate of each type, split into-
On-premises Cloud based Mobile Solutions
Grab Best Discount on Hormone Replacement Therapy (HRT) Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/66100
Hormone Replacement Therapy (HRT) Market Regional Analysis Includes:
Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)
Hormone Replacement Therapy (HRT) Insights that Study is going to provide:
Gain perceptive study of this current Hormone Replacement Therapy (HRT) sector and also possess a comprehension of the industry; Describe the Hormone Replacement Therapy (HRT) advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Hormone Replacement Therapy (HRT) market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.
Table of Content:
Global Hormone Replacement Therapy (HRT) Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Hormone Replacement Therapy (HRT) Market, by Type4. Hormone Replacement Therapy (HRT) Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion
Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/66100
For More Information Kindly Contact:
Futuristic ReportsTel: +1-408-520-9037Email: [emailprotected]Media Release: https://www.futuristicreports.com/press-releases
Follow us on Blogger @ https://futuristicreports.blogspot.com/
Posted in Hormone Replacement Therapy
Comments Off on Hormone Replacement Therapy (HRT) Market 2020 COVID19 Impact Analysis on Key Players | Spice Technologies, FreshBooks, ActCAD and Others – Latest…
Global Acute Kidney Injury Market Insights, Epidemiology and Forecast to 2030 – ResearchAndMarkets.com – Business Wire
Posted: April 27, 2020 at 2:52 pm
DUBLIN--(BUSINESS WIRE)--The "Global Acute Kidney Injury Market Insight, Epidemiology and Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Acute Kidney Injury (AKI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Kidney Injury (AKI) market size from 2017 to 2030. The report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute Kidney Injury (AKI) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Acute Kidney Injury, Discharge Diagnosed Cases of Acute Kidney Injury, Stage-Wise Discharged Diagnosed Cases of Acute Kidney Injury, Risk Factor Associated Acute Kidney Injury Cases and Renal Transplantation Associated Delayed Graft Function scenario of Acute Kidney Injury (AKI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Key Findings
This section provides glimpse of the Acute Kidney Injury (AKI) epidemiology in the 7MM:
Drug Chapters
The drug chapter segment of the AKI report encloses the detailed analysis of mid and late stage pipeline drugs. It also helps to understand the AKI clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Emerging Drugs
EA-230: Exponential Biotherapies
EA-230 is being developed by Exponential Biotherapies, is an intravenously administered chemically synthesized linear peptide, a derivative of the human pregnancy hormone used for immunomodulation. During the preclinical studies, the drug has shown anti-inflammatory properties and protects against organ failure in several animal models of sepsis or systemic inflammation which lead to acute kidney injury. Most notably, EA-230 has shown marked protective effects in the kidney during abdominal sepsis in animals. As EA-230 attenuates the proinflammatory response in neutrophils and monocytes ex vivo, and neutrophil influx in tissues during systemic inflammation in vivo is abrogated, EA-230 acts by protecting the host against the detrimental effects of neutrophils during acute systemic inflammatory diseases, thereby preventing organ damage, especially in the kidney. EA-230 is under development by Exponential Biotherapies in collaboration with Radboud University.
bRESCAP: Alloksys
RESCAP (Rescuing Alkaline Phosphatase), is an endogenous enzyme based on Alkaline Phosphatase (AP) a naturally occurring protein present in the body. It works as prophylactic and therapeutic anti-inflammatory protein that prevents ischemic injury by neutralizing and detoxifying inflammatory triggers that may derail the immune system. In acute settings, RESCAP triggers enhanced endogenous production of AP by the body, thereby boosting innate defense systems. bRESCAP is the type of RESCAP based on calf intestine from BSE free countries. It has a fast onset of action, a high dosing efficacy and a short residence time in the body (half-life of a few minutes), which makes the drug ideal for acute clinical disorder treatments.
ANG-3777 (BB3): Angion Biomedica
ANG-3777 (also known as BB3 and refanalin) is a small molecule hepatocyte growth factor/scatter factor (HGF/SF) being developed by Angion Biomedica. Its development is grounded in decades of research investigating the role of the HGF/c-Met pathway in organ repair. When an organ is injured, HGF expression peaks around 2 h but c-Met receptor expression peaks around 24-36 h, creating a mismatch between HGF and c-Met potentially resulting in suboptimal rates of organ self-repair. ANG-3777 is designed to address this challenging mismatch, supplementing endogenous HGF during peak c-MET receptor expression.
Teprasiran (QPI-1002): Quark Pharmaceuticals
Teprasiran (QPI-1002) is a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the proapoptotic gene p53, via activation of the RNA interference (RNAi) pathway being developed by Quark Pharmaceuticals. Its development is based on the proprietary concept for temporary and reversible inhibition of p53 for therapeutic purposes. P53 is a stress-response gene activated by DNA damage, hypoxia, oxidative stress, and other conditions, leading to the induction of cell cycle arrest, cell senescence or apoptosis.
ASP1128: Astellas Pharma
ASP1128 by Astellas Pharma is also known as MA-0217, is an investigational compound that is a potent and highly selective PPAR modulator. ASP1128 has the potential to have protective effects on kidney cells that are under cellular stress following CABG/V surgery by promoting fatty acid oxidation in the mitochondria. Further, ASP1128 may have the potential to reduce systemic and local inflammatory responses and oxidative stress.
Market Outlook
The global burden of acute kidney injury has increased over the years. Among the 7 major markets, the United States has reported having maximum incident cases of AKI. Though the incident of AKI is high across the US, but the condition is often undiagnosed, ultimately leading to lower treatable pool (when compared to the total incident population of the disease) that contributes to the market size of AKI.
Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
The AKI market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted AKI market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of AKI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, AKI 7MM market is expected to change in the study period 2017-2030.
Key Findings
This section includes a glimpse of the Acute Kidney Injury (AKI) 7MM market.
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017-2030. The analysis covers Acute Kidney Injury (AKI) market uptake by drugs and patient uptake by therapies.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Kidney Injury (AKI) emerging therapies.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the Acute Kidney Injury (AKI) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Companies Mentioned
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sdm5i3
Posted in Hormone Replacement Therapy
Comments Off on Global Acute Kidney Injury Market Insights, Epidemiology and Forecast to 2030 – ResearchAndMarkets.com – Business Wire
School is out. Many young people are not – the impact of lockdown on LGBTQ youth – Gay Times Magazine
Posted: April 27, 2020 at 2:52 pm
Following the announcement of the UK lockdown in March, we have all had no choice but to quickly adapt to a different way of living in order to ensure the safety of ourselves and others.
Our daily routines have been completely altered, many of our plans postponed or cancelled, and we have been unable to meet relatives and friends who we may ordinarily have seen on a regular basis. It has been tough for everyone. Unfortunately, the situation is especially difficult for the younger members of our community who are in lockdown with unsupportive families.
Research by LGBTQ youth charity, Just Like Us, suggests that LGBTQ young people may struggle more at home than cis straight young people, as they are more likely to initially confide in friends rather than a family member; the reverse is true for their non LGBTQ peers.
For so many closeted young people including some Just Like Us volunteer ambassadors moving out of home for college, university or work is an opportunity to come out and build a support network. Meeting other LGBTQ young people and moving away from home has been a life-changing experience for many of us, who kept our identities hidden from our families for many years.
The closure of universities, colleges and workplaces means that many LGBTQ young people are now separated from their chosen friends and family, and are having to re-enter unsupportive households. My co-ambassador Nicole said, Having to go from being out and living on my own, then back to being closeted in a homophobic household, has hit hard.
Anna, another ambassador, whose family is Catholic, says, I came out to my family last year after I began my second year at uni and started dating a girl. I knew they wouldnt take it well initially, but thought they would at least be able to process what Id told them by the time I came home. Now Im back home [early] they barely speak to me and when they do, they criticise me for my sinful lifestyle Being back at home with my family has definitely taken its toll on my mental health.
Our trans ambassadors face additional problems. Joel says, Im really lucky to be isolating with people who are very trans friendly and affirming, but its medical stuff thats my concern. Its causing a lot of worries around my transition. Ive recently changed from getting my Hormone Replacement Therapy (HRT) injections to gel. Im due a blood test in two weeks, but my GP isnt doing any face to face appointments so I cant have one, and if I cant have my bloods okayed at safe levels on the new HRT, my endocrinologist will probably stop it until we can prove my liver is coping.
There are other trans folk who are in similar boats. My friend has missed one injection, as he has a condition meaning he cant self-inject, and the nurse wont make an appointment to inject him at this time. Others have had their gender affirming surgeries cancelled. Theres also the fact that Gender Identity Clinics are all closed right now, so the already ridiculous wait times (currently around 26 months from referral to first appointment and 20 months between appointments for the Newcastle clinic) are only going to be longer when all this is over.
At Just Like Us, we work with LGBTQ young people in schools, many of whom are not yet out to their friends and relatives. Now that schools are closed, these kids are with their families 24/7, and if they have not yet had the chance to build a support network, this could be incredibly isolating. Many will be suppressing their identities due to the fear of being rejected by their families, and with most currently entirely dependent on their families, akt (Albert Kennedy Trust), the LGBTQ youth homelessness charity, has advised LGBTQ young people not to come out to family during the lockdown, because of the consequences of a potential negative response. In addition, the possibility that university and college courses may commence online in September will come as a huge disappointment for those who are hoping to move away from unsupportive households.
But despite this, were coming together to support one another during these difficult times, and our LGBTQ young adults are finding great ways to support themselves and one another. As an example, the Just Like Us ambassadors have set up a WhatsApp group aimed at sharing (both LGBTQ related and more general) quarantine tips, including recipes, craft ideas and self-care advice. I think we may have also broken the world record for the number of pet photos shared in one group chat, and I am completely living for it. Ive learned so much from hearing about how other ambassadors are looking after themselves during this time.
Im looking after myself by trying new hobbies, connecting with friends and not beating myself up about everything, says Sophie. Ive found that making lists with friends of stuff you guys want to do once were out of lockdown has really given me some perspective on whats important.
Just Like Us have also launched a new social media campaign, #JLUatHome, in order to support young LGBTQ people during lockdown. The campaign has consisted of a range of content so far, including messages of support to isolated LGBTQ young people, film and book recommendations, as well as the opportunity to ask Just Like Us ambassadors questions. Through this period, we are really seeing the benefits of being part of an LGBTQ community that is still connected from afar.
If you are a LGBTQ young person, we would love you to join us by listening to our latest podcast episode, which you can listen to here. This month, ambassadors Isaac, Elly and Arber will discuss more in depth what its like being LGBTQ at home. If youre an LGBTQ teenager in the UK, we also want to welcome you into our digital ambassador team which is another way to be part of this incredible community.
Finally, if youre reading this article and want to help us to help LGBTQ young people during this difficult time, you can also make a donation to Just Like Us, but only if you are in a position to do so. You can make a gift here. Thank you!
Related: Volunteering for Just Like Us gave me confidence in my identity as a young, gay, mixed race Muslim.
Related: The invisible have voices too listen to trans youth.
Read the original here:
School is out. Many young people are not - the impact of lockdown on LGBTQ youth - Gay Times Magazine
Posted in Hormone Replacement Therapy
Comments Off on School is out. Many young people are not – the impact of lockdown on LGBTQ youth – Gay Times Magazine
Mom May Not Be Allowed To Be Present At Birth Of First Child – BabyGaga
Posted: April 27, 2020 at 2:52 pm
Olivia Rowlands and her husband Sam, who are expecting a baby girl in July via surrogate, may not be allowed to be present at the birth of their first child. The baby is being carried by Olivias cousin, Ellie Hutchinson, after Olivia underwent treatment for bowel cancer left, which left her unable to bear children.
The coronavirus lockdown has forced the expectant parents to watch the pregnancy via video, and new hospital protocols may prevent them from witnessing the birth of their daughter. Olivia, 31, an elementary school teacher, was diagnosed with bowel cancer in 2017 and went into early menopause after 29 sessions of radiotherapy.
RELATED:Pregnant Woman With Severe COVID-19 Gives Birth To Healthy Boy & Recovers
Before her treatment, she had frozen four embryos at Ninewells Hospital in Dundee. Her cousin Ellie, 34, offered to be the couples surrogate even though the two women had not seen each other since they were children. Fortunately, after an initial miscarriage scare early on, Ellies pregnancy has gone perfectly. The couples happiness, however, has been tempered by the coronavirus pandemic.
Speaking to Drivetime with John Beattie on BBC Radio Scotland, Olivia said, "We froze four embryos back in November which we had implanted into my cousin Ellie and we are now 28 weeks pregnant. But we haven't seen her for two months. She went into self-isolation two weeks before the lockdown started because she was pregnant and wanted to be careful and stay safe.
She added that they have been able to Facetime but havent been able to accompany her cousin to her prenatal appointments or be there when Ellie heard their daughters heartbeat for the first time. Thankfully, Ellie recorded the ultrasound and sent it to the couple. Olivia is grateful that a family member is carrying her daughter although she wishes she could speak to her unborn child directly or feel her cousins baby bump.
READ NEXT:Three Healthcare Workers Share Experience Of Being Pregnant During COVID-19 Crisis
The couple hopes that by July the lockdown restrictions will have been lessened so that they can be there for the birth of their child and their parents, who live abroad, can visit the newborn. For now, the couple is focused on the positives. Olivia is due for a two-year scan next month, which will hopefully confirm that her cancer is definitively gone. Meanwhile, she is undergoing hormone replacement therapy.
Source: BBC
Judge Rules That Tennessee Can't Block Abortion During The Coronavirus Pandemic
Mark Lugris is a Junior Editor and Contributing Writer to BabyGaga. A University of Connecticut graduate with a BA in English and Creative Writing, Mark has worked as a Reporter and Editor for news publications in Connecticut and Boston. He was the Editor-in-chief of PopGuide, a travel and lifestyle magazine in Madrid, Spain, and was the Online Public Relations and Communications Manager for Swarovski in Switzerland. Since 2016, Mark has been the CEO and Content Director of Lugris Communications. He is a mid-century modern design enthusiast, film and photography fan, dog lover, and an avid traveler.
See the original post here:
Mom May Not Be Allowed To Be Present At Birth Of First Child - BabyGaga
Posted in Hormone Replacement Therapy
Comments Off on Mom May Not Be Allowed To Be Present At Birth Of First Child – BabyGaga
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 – CMI – GlobeNewswire
Posted: April 27, 2020 at 2:52 pm
SEATTLE, April 23, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to be valued at US$ 43,205.8 million in 2020, and is expected to exhibit a CAGR of 12.7% during the forecast period (2020-2027).
Key Trends:
Key trends in the market include viral disease outbreaks, the increasing prevalence of chronic lymphocytic leukemia, and demand for immune globulin products in the market.
According to the American Cancer Society around 60,530 new cases of leukemia will be diagnosed in the U.S in 2020 out of which 21,040 new cases will be of chronic lymphocytic leukemia (CLL).
Similarly, according to the Cancer Research UK, around 3,500 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in the U.K in 2017.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3790
Moreover, the growing demand for immune globulin (IG) products is expected to drive the human immunoglobulin (ph4) for intravenous injection (COVID-19) market growth. For instance, on August 12, 2019, the U.S. Food and Drug Administration (FDA) confirmed that demand for immune globulin products has increased in recent years and there is a shortage of Immune Globulin (Subcutaneous) (IGSC) and Immune Globulin (Intravenous) (IGIV) products in the U.S. The U.S. Food and Drug Administration is working closely with manufacturers such as Asceniv, Bivigam, Octagam, Panzyga, Privigen and others of various immune globulin (intravenous) (IGIV) products to help mitigate the supply situation for IG products.
Key Market Takeaways:
Key players operating in market are
Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc., China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
Buy this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3790
Market Segmentation:
Related Topics:
HEALTHCARE CONTRACT RESEARCH OUTSOURCING MARKET
Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices. Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.
Read more @ https://www.coherentmarketinsights.com/market-insight/healthcare-contract-research-outsourcing-market-3788
ANDROGEN REPLACEMENT THERAPY MARKET
Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level.
Read more @ https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787
Read the original post:
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - GlobeNewswire
Posted in Hormone Replacement Therapy
Comments Off on Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 – CMI – GlobeNewswire